Duchenne Gene Therapy Shows No Alteration of Cardiac Outcomes in Phase 3 EMBARK Study

After 52 weeks of treatment, no significant differences were found in cardiac MRI measures such as ejection fraction, end diastolic volume, or circumferential strain between the two groups.:

Source: Neurology Read More